当前位置: 首页 >> 检索结果
2181. Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study.
作者: Paul Yang.;Laura P Pardon.;Allen C Ho.;Andreas K Lauer.;Dan Yoon.;Shannon E Boye.;Sanford L Boye.;Alejandro J Roman.;Vivian Wu.;Alexandra V Garafalo.;Alexander Sumaroka.;Malgorzata Swider.;Iryna Viarbitskaya.;Tomas S Aleman.;Mark E Pennesi.;Christine N Kay.;Kenji P Fujita.;Artur V Cideciyan.
来源: Lancet. 2024年404卷10456期962-970页
Leber congenital amaurosis 1 (LCA1), caused by mutations in GUCY2D, is a rare inherited retinal disease that typically causes blindness in early childhood. The aim of this study was to evaluate the safety and preliminary efficacy of ascending doses of ATSN-101, a subretinal AAV5 gene therapy for LCA1.
2194. Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
作者: Sung-Jin Hong.;Seung-Jun Lee.;Sang-Hyup Lee.;Jong-Young Lee.;Deok-Kyu Cho.;Jin Won Kim.;Sang Min Kim.;Seung-Ho Hur.;Jung Ho Heo.;Ji-Yong Jang.;Jin Sin Koh.;Hoyoun Won.;Jun-Won Lee.;Soon Jun Hong.;Dong-Kie Kim.;Jeong Cheon Choe.;Jin Bae Lee.;Soo-Joong Kim.;Tae-Hyun Yang.;Jung-Hee Lee.;Young Joon Hong.;Jong-Hwa Ahn.;Yong-Joon Lee.;Chul-Min Ahn.;Jung-Sun Kim.;Young-Guk Ko.;Donghoon Choi.;Myeong-Ki Hong.;Yangsoo Jang.;Byeong-Keuk Kim.; .
来源: Lancet. 2024年404卷10457期1029-1039页
Despite the detailed imaging information provided by optical coherence tomography (OCT) during percutaneous coronary intervention (PCI), clinical benefits of this imaging technique in this setting remain uncertain. The aim of the OCCUPI trial was to compare the clinical benefits of OCT-guided versus angiography-guided PCI for complex lesions, assessed as the rate of major adverse cardiac events at 1 year.
2196. Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial.
作者: Chao Gao.;Xingqiang He.;Fan Ouyang.;Zhihui Zhang.;Guidong Shen.;Mingxing Wu.;Ping Yang.;Likun Ma.;Feng Yang.;Zheng Ji.;Hua Wang.;Yanqing Wu.;Zhenfei Fang.;Hong Jiang.;Shangyu Wen.;Yi Liu.;Fei Li.;Jingyu Zhou.;Bin Zhu.;Yunpeng Liu.;Ruining Zhang.;Tingting Zhang.;Ping Wang.;Jianzheng Liu.;Zhiwei Jiang.;Jielai Xia.;Robert-Jan van Geuns.;Davide Capodanno.;Scot Garg.;Yoshinobu Onuma.;Duolao Wang.;Patrick W Serruys.;Ling Tao.; .
来源: Lancet. 2024年404卷10457期1040-1050页
The long-term impact of drug-coated balloon (DCB) angioplasty for the treatment of patients with de novo coronary artery lesions remains uncertain. We aimed to assess the non-inferiority of DCB angioplasty with rescue stenting to intended drug-eluting stent (DES) deployment for patients with de novo, non-complex coronary artery lesions.
2197. Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up.
作者: Holger Thiele.;Jacob E Møller.;Jose P S Henriques.;Margriet Bogerd.;Melchior Seyfarth.;Daniel Burkhoff.;Petr Ostadal.;Richard Rokyta.;Jan Belohlavek.;Steffen Massberg.;Marcus Flather.;Matthias Hochadel.;Steffen Schneider.;Steffen Desch.;Anne Freund.;Hans Eiskjær.;Norman Mangner.;Janine Pöss.;Amin Polzin.;P Christian Schulze.;Carsten Skurk.;Uwe Zeymer.;Christian Hassager.; .
来源: Lancet. 2024年404卷10457期1019-1028页
Percutaneous active mechanical circulatory support (MCS) devices are being increasingly used in the treatment of acute myocardial infarction-related cardiogenic shock (AMICS) despite conflicting evidence regarding their effect on mortality. We aimed to ascertain the effect of early routine active percutaneous MCS versus control treatment on 6-month all-cause mortality in patients with AMICS.
|